Prognostic Impact of Baseline Hemoglobin Levels on Long‐Term Thrombotic and Bleeding Events After Percutaneous Coronary Interventions

Background Association of baseline hemoglobin levels with long‐term adverse events after percutaneous coronary interventions has not been yet thoroughly defined. We aimed to assess the clinical impact of baseline hemoglobin on long‐term ischemic and bleeding risk after percutaneous coronary intervention. Methods and Results Using the pooled individual patient‐level data from the 3 percutaneous coronary intervention studies, we categorized 19 288 patients into 4 groups: high‐normal hemoglobin (≥14.0 g/dL; n=7555), low‐normal hemoglobin (13.0–13.9 g/dL in men and 12.0–13.9 g/dL in women; n=5303), mild anemia (11.0–12.9 g/dL in men and 11.0–11.9 g/dL in women; n=4117), and moderate/severe anemia (<11.0 g/dL; n=2313). Median follow‐up duration was 3 years. Low‐normal hemoglobin, mild anemia, and moderate/severe anemia correlated with significant excess risk relative to high‐normal hemoglobin for GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Trial) moderate/severe bleeding, with adjusted hazard ratios of 1.22 (95% CI, 1.04–1.44), 1.73 (95% CI, 1.47–2.04), and 2.31 (95% CI, 1.92–2.78), respectively. Moderate/severe anemia also correlated with significant excess risk relative to high‐normal hemoglobin for the ischemic composite end point of myocardial infarction/ischemic stroke (adjusted hazard ratio, 1.33; 95% CI, 1.11–1.60), whereas low‐normal hemoglobin and mild anemia did not. However, the excess risk of low‐normal hemoglobin, mild anemia, and moderate/severe anemia relative to high‐normal hemoglobin remained significant for ischemic stroke and for mortality. Conclusions Decreasing baseline hemoglobin correlated with incrementally higher long‐term risk for major bleeding, ischemic stroke, and mortality after percutaneous coronary intervention. Even within normal range, lower baseline hemoglobin level correlated with higher ischemic and bleeding risk.

[1]  D. Pittrow,et al.  Prevalence of anemia in elderly patients in primary care: impact on 5-year mortality risk and differences between men and women , 2009 .

[2]  J. Spertus,et al.  Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. , 2016, JAMA.

[3]  G. Fonarow,et al.  Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. , 2002, Journal of the American College of Cardiology.

[4]  A. Defranco,et al.  Prognostic Implication of Anemia on In-Hospital Outcomes After Percutaneous Coronary Intervention , 2004, Circulation.

[5]  T. Akasaka,et al.  Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. , 2013, Journal of the American College of Cardiology.

[6]  R. Giugliano,et al.  Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes , 2005, Circulation.

[7]  P. Levy,et al.  Acute dilutional anemia and critical left anterior descending coronary artery stenosis impairs end organ oxygen delivery. , 1996, The Journal of trauma.

[8]  D. Sane,et al.  The cardiovascular effects of erythropoietin. , 2003, Cardiovascular research.

[9]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[10]  A. Lincoff,et al.  Effect of anemia on hemorrhagic complications and mortality following percutaneous coronary intervention. , 2007, The American journal of cardiology.

[11]  Laura Mauri,et al.  2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.

[12]  D. Wijeysundera,et al.  Risk Associated With Preoperative Anemia in Cardiac Surgery: A Multicenter Cohort Study , 2008, Circulation.

[13]  M. Zwahlen,et al.  The Impact of Anemia on Long-Term Clinical Outcome in Patients Undergoing Revascularization With the Unrestricted Use of Drug-Eluting Stents , 2012, Circulation. Cardiovascular interventions.

[14]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[15]  Christina L. Clarke,et al.  Association of longitudinal measures of hemoglobin and outcomes after hospitalization for heart failure. , 2010, American heart journal.

[16]  Marco Valgimigli,et al.  [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] , 2018, Kardiologia polska.

[17]  Takeshi Kimura,et al.  Prognostic implications of anemia with or without chronic kidney disease in patients undergoing elective percutaneous coronary intervention. , 2013, International journal of cardiology.

[18]  F Unger,et al.  Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. , 2001, The New England journal of medicine.

[19]  Y. Hayashi,et al.  Comparison of Everolimus-Eluting and Sirolimus-Eluting Coronary Stents: 1-Year Outcomes from the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial (RESET) , 2012, Circulation.

[20]  A. Zaman,et al.  Meta-Analysis of the Prognostic Impact of Anemia in Patients Undergoing Percutaneous Coronary Intervention. , 2016, The American journal of cardiology.

[21]  Samin K. Sharma,et al.  Impact of major bleeding on long-term mortality in anemic versus nonanemic patients undergoing percutaneous coronary intervention using bivalirudin. , 2014, The American journal of cardiology.

[22]  S. Yusuf,et al.  Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. , 2010, European heart journal.

[23]  Nutritional anaemias. Report of a WHO scientific group. , 1968, World Health Organization technical report series.

[24]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[25]  Takeshi Kimura,et al.  Impact of Baseline Thrombocytopenia on Bleeding and Mortality After Percutaneous Coronary Intervention. , 2018, The American journal of cardiology.

[26]  M. Nobuyoshi,et al.  Long-term safety and efficacy of sirolimus-eluting stents versus bare-metal stents in real world clinical practice in Japan , 2011, Cardiovascular intervention and therapeutics.

[27]  H. Miyata,et al.  Relation of Baseline Hemoglobin Level to In-Hospital Outcomes in Patients Who Undergo Percutaneous Coronary Intervention (from a Japanese Multicenter Registry). , 2017, American Journal of Cardiology.